1. Introduction {#sec1}
===============

Neuroblastoma is the most frequently diagnosed extracranial pediatric malignancy in children younger than 12 months, which accounts for almost 10% of all pediatric malignancies and 15% of pediatric cancer-related deaths \[[@B1]\]. Neuroblastoma is a highly heterogeneous tumor with a wide range of clinical symptoms. For instance, some patients with innocent tumors have spontaneous regression, while others have poor prognosis even after receiving intensive treatment because of the distant metastasis \[[@B2]\]. Overall, neuroblastoma can be classified into low-, intermediate-, and high-risk groups depending on the clinical feature, pathological phenotypes, and prognostic factors \[[@B3]\]. Despite the great progresses made in multimode treatments for neuroblastoma, the survival rate remains unsatisfying. The overall 5-year survival rate is around 70%; however, the survival rate for high-risk patients is lower than 40% \[[@B4]\]. This poor prognosis may be partially attributed to widespread metastasis at the time of diagnosis \[[@B5]\].

Familial neuroblastoma with driver germline mutation is rare, accounting for approximately 1-2% of all cases \[[@B6]\]. The genetic alterations in the *PHOX2B* and *ALK* genes play an important role in familial neuroblastoma \[[@B7], [@B8]\]. However, the genetic mechanism of the sporadic neuroblastoma is poorly understood. Some environmental factors have been proposed as potential risk factors, such as maternal medication use, dwelling condition, childhood infections, conception, and pregnancy exposures \[[@B9], [@B10]\]. To date, a direct link between neuroblastoma and environmental factors is still missing. Excitingly, the progresses in the understanding of human genome and genotyping technologies have made the genome-wide association study (GWAS) a powerful tool to study inherited genetic variations, which are associated with complex human diseases (e.g., cancer) \[[@B11]\]. The first neuroblastoma GWAS was performed by Maris et al. in 2008. They found that *CASC15* gene polymorphisms were significantly related to neuroblastoma susceptibility \[[@B12]\]. Later on, the same group reported that common variants in *BARD1* gene were associated with high-risk neuroblastoma \[[@B13]\], and polymorphisms within *DUSP12*, *DDX4*, *IL31RA*, and *HSD17B12* were associated with low-risk neuroblastoma \[[@B14]\]. In 2011, Wang et al. demonstrated that *LMO1* gene polymorphisms could alter the neuroblastoma susceptibility \[[@B15]\]. Diskin et al. proved that polymorphisms in *LIN28B* and *HACE1* genes were also able to alter susceptibility to neuroblastoma \[[@B16]\]. Furthermore, the association of the polymorphisms in *TP53* \[[@B17]\] and *MMP20* \[[@B18]\] genes with the neuroblastoma risk was also discovered by recent GWASs successively. In addition, candidate gene approaches have been useful in identifying potential variants associated with neuroblastoma. For instance, Capasso et al. found that common variants in *NEFL* were associated with neuroblastoma susceptibility with 2101 neuroblastoma cases and 4202 controls of Caucasian ancestry as well as 459 neuroblastoma patients and 809 cancer-free controls of Italian descent \[[@B19]\]. They also discover a functional variant in the *CDKN1B* gene modifying neuroblastoma susceptibility \[[@B20]\]. Moreover, several other predisposing genes including *BARD1* \[[@B21]\], *FAS* and *FASL* \[[@B22]\], *XPG* \[[@B23]\], *HOTAIR* \[[@B24]\], and *ERCC1*/*XPF* \[[@B25]\] have been discovered through candidate gene approaches.

The human genome continuously suffers from DNA damages caused by exogenous (e.g., ultraviolet light, ionizing radiation chemicals) and endogenous (intracellular hydrolysis and metabolic by-products) factors. For example, the reactive oxygen species can give rise to oxidant-induced base lesions \[[@B26]\], which may eventually lead to genomic instability and increase tumor susceptibility if not repaired accurately. Hence, the DNA repair systems play important roles in maintaining the genomic integrity and cellular normal physiological function \[[@B27]\].

Base excision repair (BER) is one of the most important repair mechanisms for DNA lesions. It is widely accepted that BER is the primary pathway for repairing numerous oxidized and alkylated bases \[[@B28]\]. BER maintains genome integrity through recognition and excision of damaged bases. The protein product of the *apurinic/apyrimidinic endonuclease 1* (*APEX1*) gene is one of critical enzymes in this DNA repair pathway \[[@B29]\]. It is reasonable to speculate that functional single nucleotide polymorphisms (SNPs) in *APEX1* may affect DNA repair ability by affecting expression or function of the gene, which may further cause cell dysfunction, mutagenesis, and eventually tumorigenesis \[[@B30]\]. *APEX1* gene polymorphisms have been shown to associate with colorectal cancer \[[@B31]\], cervical cancer \[[@B32]\], and ovarian cancer \[[@B33]\]. However, no publications have reported the associations of *APEX1* gene polymorphisms with neuroblastoma risk. Therefore, we performed this three-center case-control study to assess such association in Chinese children.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

In the current three-center case-control research, a total of 469 histopathologically diagnosed neuroblastoma cases and 998 cancer-free controls of Chinese origin were recruited (Supplemental [Table 1](#supplementary-material-1){ref-type="supplementary-material"}). Among them, 275 cases and 531 controls were recruited from Guangzhou \[[@B34]--[@B37]\], 118 cases and 281 controls from Zhengzhou \[[@B38]--[@B40]\], and the remaining 76 cases and 281 controls from Xi\'an \[[@B41]\]. Informed consent was signed by the parents or guardians of all participants. The research protocol was authorized by the institutional review boards of corresponding institutions.

2.2. Polymorphism Selection and Genotyping {#sec2.2}
------------------------------------------

Potential functional polymorphisms in the *APEX1* gene were identified through the dbSNP database (<http://www.ncbi.nlm.nih.gov/>) and SNPinfo (<http://snpinfo.niehs.nih.gov/>) \[[@B42]\]. Briefly, we searched the SNPs located in the untranslated regions, two terminals, and exon of the *APEX1* gene. Additional selection criteria were referred from our previous publication \[[@B43]\]. Three SNPs (rs1130409 T\>G, rs1760944 T\>G, and rs3136817 T\>C) in the *APEX1* gene were eventually selected. As shown in Supplemental [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}, there is no significant linkage disequilibrium (*R* ^2^ \< 0.8) among these three included SNPs for Chinese Han subjects (*R* ^2^ = 0.130 between rs1760944 and rs3136817, *R* ^2^ = 0.076 between rs1760944 and rs1130409, and *R* ^2^ = 0.131 between rs3136817 and rs1130409). Genomic DNA was extracted from venous blood of participants applying the TIANamp Blood DNA Kit (TIANGEN Biotech Co. Ltd., Beijing, China). Then, the purified DNA samples were genotyped for the selected polymorphisms by the standard TaqMan real-time PCR \[[@B44]--[@B47]\]. To ensure the reliability of the results, 10% of the DNA samples were chosen randomly for a second-time genotyping. All duplicate samples receive a concordance rate of 100%.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Deviation from the Hardy-Weinberg equilibrium (HWE) for the selected SNPs in all controls was checked by a goodness-of-fit *χ* ^2^ test. A two-sided chi-square test was used to compare distributions of demographics and allele frequencies between all cases and controls. By unconditional logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for assessing the association between *APEX1* polymorphisms and neuroblastoma risk. Furthermore, we conducted stratified analysis according to age, gender, tumor origin site, and clinical stage. All statistical analyses were performed by applying version 9.4 SAS software (SAS Institute, NC, USA). The *P* values \< 0.05 were thought to be statistically significant.

3. Results {#sec3}
==========

3.1. Associations between *APEX1* Polymorphisms and Neuroblastoma Risk {#sec3.1}
----------------------------------------------------------------------

In general, this three-center case-control study contains 469 cases and 998 controls, of which genotyping was successfully performed in 469 cases and 997 controls. As shown in [Table 1](#tab1){ref-type="table"}, the observed genotype frequencies of the three polymorphisms are consistent with HWE in control subjects (rs1130409: HWE = 0.190, rs1760944: HWE = 0.231, and rs3136817: HWE = 0.783). Unfortunately, after adjusting for age and gender, we failed to find significant association between the selected *APEX1* polymorphisms and neuroblastoma risk in the single locus analysis among combined subjects ([Table 1](#tab1){ref-type="table"}) and among subjects from each center (Supplemental [Table 2](#supplementary-material-1){ref-type="supplementary-material"}). We further assessed the combined effect of protective polymorphisms of *APEX1* gene on neuroblastoma risk. Subjects carrying 1-3 combined protective genotypes of *APEX1* have a lower risk of neuroblastoma when compared with those without a protective genotype, though not statistically significant (adjusted OR = 0.81, 95%CI = 0.64‐1.01, *P* = 0.064) ([Table 1](#tab1){ref-type="table"}).

3.2. Stratification Analysis {#sec3.2}
----------------------------

To evaluate the effects of selected *APEX1* polymorphisms on neuroblastoma risk among different subgroups, stratified analysis was conducted based on the age, gender, site of tumor origin, and clinical stage ([Table 2](#tab2){ref-type="table"}). Null correlations were found between two polymorphisms (rs1760944 T\>G and rs3136817 T\>C) and neuroblastoma risk. Interestingly, we detected that subjects with rs1130409 GG genotype have significantly decreased neuroblastoma risk in the male subgroup (adjusted OR = 0.67, 95%CI = 0.44‐0.995, *P* = 0.047) compared with the reference group. To assess the cumulative effects of protective genotypes among subgroups, we further performed a combined analysis. Results show that subjects harboring 1-3 protective genotypes had a significantly reduced neuroblastoma risk in the following subgroups: age \> 18 months (adjusted OR = 0.70, 95% = 0.52‐0.94, *P* = 0.016) and males (adjusted OR = 0.64, 95%CI = 0.47‐0.87, *P* = 0.005).

4. Discussion {#sec4}
=============

With an aim to investigate the effect of *APEX1* gene polymorphisms on neuroblastoma risk, we performed this current three-center case-control study in Chinese population. Neither rs1760944 T\>G nor rs3136817T\>C significantly modified neuroblastoma susceptibility. However, it is noteworthy that rs1130409 GG genotype was significantly associated with reduced neuroblastoma risk in the male subgroup.

The *APEX1* gene is mapped to chromosome 14q11.2-q12 and comprises five exons and four introns with 2.21 kb length. It encodes a nuclease acting as a rate-limiting enzyme in the BER pathway \[[@B48]\]. When exposed to endogenous and exogenous mutagens, apurinic/apyrimidinic (AP) sites are produced in DNA. *APEX1* can hydrolyze a 5′-phosphodiester bond at the AP site, thereby protecting cells against the accumulation of AP sites in DNA \[[@B49]\]. In addition, *APEX1* can act as 3′-phosphodiesterase which could hydrolyze 3′-blocking fragments of oxidized DNA, thus producing normal nucleotide 3′-droxyl terminals. These ends are requisite for DNA repair synthesis and ligation of gaps generated from single- or double-strand breaks \[[@B50], [@B51]\]. *APEX1* is endonuclease and phosphodiesterase in the BER pathway. Polymorphisms in the *APEX1* gene may alter gene expression so as to affect the activity of DNA repair and the accumulation of damaged DNA, eventually leading to carcinogenesis.

Variants in the *APEX1* gene are found to associate with susceptibility to several cancers, including cervical cancer \[[@B32]\], glioblastoma \[[@B52]\], bladder cancer \[[@B53]\], and lung cancer \[[@B49], [@B54]\]. To date, many SNPs in the *APEX1* gene have been identified \[[@B55]\]. Among them, polymorphisms rs1130409 T\>G and rs1760944 T\>G were extensively studied. Polymorphism rs1130409 T\>G in the fifth exon leads to Asp148Glu residue transition in the carboxy-terminus but has no direct effect on DNA-binding and endonuclease activities of APEX1. However, polymorphism rs1760944 T\>G in the promoter region may be a pathogenic SNP associated with cancer risk \[[@B54]\]. The rs1130409 has been widely explored in a wide spectrum of cancers, such as bladder cancer \[[@B53]\]. De Ruyck et al. suggested that rs1130409 T\>G increased lung cancer risk in Caucasians \[[@B56]\], but Deng et al. found that this polymorphism reduced the susceptibility to lung cancer in Asians \[[@B57]\]. The rs1760944 T\>G, one of the most frequently investigated SNPs in the *APEX1* gene, is also related to cancer susceptibility, such as nasopharyngeal carcinoma (NPC) \[[@B55]\] and glioblastoma \[[@B52]\]. Lo et al. suggested that patients with genotype rs1760944 GT or GG had lower lung cancer risk compared with those with rs1760944 TT \[[@B49]\]. One study performed by Kang et al. showed that the genotype of rs1760944 GG or GT may act as a protective genotype for breast cancer \[[@B58]\]. Li et al. found that genotype rs1760944 GG was associated with reduced risk of NPC compared with other genotypes, but the results did not reach statistical significance. More recently, one study conducted by Lu et al. confirmed that individuals with genotype rs1760944 GT or GG had significantly decreased NPC susceptibility than those with genotype rs1760944 TT \[[@B59]\]. These findings indicated that rs1760944 G allele may exert protective effects against several cancers. In addition, rs3136817 T\>C is one of the polymorphisms in the *APEX1* gene which is investigated relatively less frequently. However, there are still some reports about association between polymorphism rs3136817 T\>C and cancer risk. For instance, Zhu et al. showed that rs3136817 TC genotype of the *APEX1* gene was associated with lower risk of bladder cancer \[[@B60]\]. However, a research performed by Li et al. revealed null correlation between *APEX1* rs3136817 T\>C and risk of severe radiation-induced pneumonitis after radiotherapy among patients with lung cancer \[[@B61]\]. A recent study conducted by Wang et al. indicated that the rs3136817 TC heterozygous genotype of *APEX1* has a potential protective effect for breast cancer, which may be owing to positive effect of rs3136817 TC genotype on DNA repair activity \[[@B62]\]. The conflicting association between *APEX1* gene polymorphisms and cancer risk may be explained by the differences in the sample sizes, race, cancer types, selection criteria for subjects, and environmental exposures. Therefore, the conclusion associated between *APEX1* polymorphisms and cancer risk should be specified in a particular cancer type and population.

Herein, we for the first time investigated the association between the *APEX1* gene SNPs and neuroblastoma risk. No significant association was found in the single locus analysis or combined analysis. Several reasons may help to explain the unexpected negative results: (1) the role of a polymorphism in cancer susceptibility might be tissue- and ethnicity-dependent and (2) the sample size of this study was too small to detect a real association. Although no significant effect was found in the overall analysis, age and gender may modify the results. In the stratified analysis, we found that rs1130409 GG genotype significantly decreased the risk of neuroblastoma in the male subgroup. To date, the rs1130409 T\>G of the *APEX1* gene is the most extensively studied SNP. Moreover, we also found that the presence of 1-3 protective genotypes provided a protective effect for children \> 18 months of age and boys. It should be noted that these significant results may be just chance findings in the stratification analysis because of relatively small sample size.

There are several accompanied limitations. First, although subjects in this current study were recruited from three independent hospitals, the sample size remains moderate, especially for the stratified analysis. As a result, the statistical powers were ineluctably whittled. Second, only three polymorphisms in the *APEX1* gene were investigated. Other potentially functional *APEX1* polymorphisms should be assessed. Third, the subjects involved in this study are Chinese; therefore, the conclusions obtained from this study may not apply to other ethnicities. Fourth, only genetic analysis was performed in neuroblastoma risk. Other environmental factors such as living environment, dietary habits, and childhood or parental exposure should be considered, as neuroblastoma is a heterogeneous disease with a complicated etiology.

5. Conclusions {#sec5}
==============

In conclusion, our present data suggest that *APEX1* polymorphisms affect neuroblastoma susceptibility in a low-penetrance manner. Well-designed multicenter studies with larger sample size are needed to confirm our findings. Furthermore, functional validation should be performed to clarify the underlying mechanisms by which *APEX1* gene polymorphisms affect neuroblastoma susceptibility.
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Supplemental Table 1: frequency distribution of selected characteristics in cases and controls. Supplemental Table 2: association between APEX1 gene polymorphisms and neuroblastoma risk (divided subjects). Supplemental Figure 1: linkage disequilibrium analysis for the three selected polymorphisms in the APEX1 gene in the Han Chinese population consisting of CHS (Southern Han Chinese) and CHB (Han Chinese in Beijing, China) subjects using data from LDlink online software (<https://ldlink.nci.nih.gov/?tab=ldmatrix>).

###### 

Click here for additional data file.

###### 

Association between *APEX1* gene polymorphisms and neuroblastoma risk.

  Genotype                                     Cases (*N* = 469)   Controls (*N* = 997)^a^   *P* ^b^   Crude OR (95% CI)   *P*     Adjusted OR (95% CI)^c^   *P* ^c^
  -------------------------------------------- ------------------- ------------------------- --------- ------------------- ------- ------------------------- ---------
  rs1130409 (HWE = 0.190)                                                                                                                                    
   TT                                          175 (37.31)         340 (34.10)                         1.00                        1.00                      
   TG                                          216 (46.06)         467 (46.84)                         0.90 (0.70-1.15)    0.389   0.90 (0.70-1.15)          0.390
   GG                                          78 (16.63)          190 (19.06)                         0.80 (0.58-1.10)    0.167   0.79 (0.58-1.09)          0.159
   Additive                                                                                  0.367     0.89 (0.77-1.04)    0.157   0.89 (0.76-1.04)          0.151
   Dominant                                    294 (62.69)         657 (65.90)               0.230     0.87 (0.69-1.09)    0.230   0.87 (0.69-1.09)          0.226
   Recessive                                   391 (83.37)         807 (80.94)               0.262     0.85 (0.63-1.13)    0.263   0.84 (0.63-1.13)          0.250
  rs1760944 (HWE = 0.231)                                                                                                                                    
   TT                                          155 (33.05)         334 (33.50)                         1.00                        1.00                      
   TG                                          230 (49.04)         470 (47.14)                         1.05 (0.82-1.35)    0.674   1.06 (0.83-1.35)          0.665
   GG                                          84 (17.91)          193 (19.36)                         0.94 (0.68-1.29)    0.694   0.94 (0.68-1.29)          0.700
   Additive                                                                                  0.736     0.98 (0.84-1.15)    0.802   0.98 (0.84-1.15)          0.810
   Dominant                                    314 (66.95)         663 (66.50)               0.864     1.02 (0.81-1.29)    0.864   1.02 (0.81-1.29)          0.854
   Recessive                                   385 (82.09)         804 (80.64)               0.509     0.91 (0.69-1.21)    0.509   0.91 (0.69-1.21)          0.511
  rs3136817 (HWE = 0.783)                                                                                                                                    
   TT                                          396 (84.43)         815 (81.75)                         1.00                        1.00                      
   TC                                          67 (14.29)          172 (17.25)                         0.80 (0.59-1.09)    0.158   0.80 (0.59-1.09)          0.163
   CC                                          6 (1.28)            10 (1.00)                           1.24 (0.45-3.42)    0.685   1.23 (0.44-3.41)          0.692
   Additive                                                                                  0.329     0.87 (0.66-1.14)    0.300   0.87 (0.66-1.14)          0.306
   Dominant                                    73 (15.57)          182 (18.25)               0.205     0.83 (0.61-1.11)    0.206   0.83 (0.62-1.11)          0.211
   Recessive                                   463 (98.72)         987 (99.00)               0.635     1.28 (0.46-3.54)    0.636   1.27 (0.46-3.52)          0.644
  Combined effect of protective genotypes^d^                                                                                                                 
   0                                           305 (65.03)         598 (59.98)                         1.00                        1.00                      
   1-3                                         164 (34.97)         399 (40.02)               0.064     0.81 (0.64-1.01)    0.064   0.81 (0.64-1.01)          0.064

OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium. ^a^One was failed in genotyping. ^b^The *χ* ^2^ test for genotype distributions between neuroblastoma patients and cancer-free controls. ^c^Adjusted for age and gender. ^d^Protective genotypes were rs1130409 GG, rs1760944 GG, and rs3136817 TC/TT.

###### 

Stratification analysis for association between *APEX1* gene genotypes and neuroblastoma susceptibility.

  Variables          rs1130409 (case/control)   AOR (95% CI)^a^   *P* ^a^                 rs1760944 (case/control)   AOR (95% CI)^a^   *P* ^a^   rs3136817 (case/control)   AOR (95% CI)^a^   *P* ^a^   Protective genotypes (case/control)   AOR (95% CI)^a^    *P* ^a^                                             
  ------------------ -------------------------- ----------------- ----------------------- -------------------------- ----------------- --------- -------------------------- ----------------- --------- ------------------------------------- ------------------ --------- --------- -------- ---------------------- -----------
  Age (month)                                                                                                                                                                                                                                                                                                        
   ≤18               138/319                    31/71             1.01 (0.64-1.62)        0.958                      135/314           34/76     1.04 (0.66-1.63)           0.874             139/325   30/65                                 1.09 (0.68-1.75)   0.733     101/234   68/156   1.01 (0.70-1.46)       0.949
   \>18              253/488                    47/119            0.76 (0.52-1.09)        0.137                      250/490           50/117    0.84 (0.58-1.21)           0.344             257/490   43/117                                0.70 (0.48-1.02)   0.066     204/364   96/243   **0.70 (0.52-0.94)**   **0.016**
  Gender                                                                                                                                                                                                                                                                                                             
   Female            155/335                    41/79             1.12 (0.73-1.71)        0.602                      161/336           35/78     0.94 (0.60-1.46)           0.776             162/238   34/76                                 0.93 (0.60-1.46)   0.763     114/249   82/165   1.09 (0.77-1.53)       0.643
   Male              236/472                    37/111            **0.67 (0.44-0.995)**   **0.047**                  224/468           49/115    0.89 (0.61-1.29)           0.527             234/477   39/106                                0.75 (0.51-1.12)   0.166     191/349   82/234   **0.64 (0.47-0.87)**   **0.005**
  Sites of origin                                                                                                                                                                                                                                                                                                    
   Adrenal gland     136/807                    26/190            0.80 (0.51-1.25)        0.323                      134/804           28/193    0.87 (0.56-1.34)           0.521             137/815   25/182                                0.83 (0.53-1.31)   0.430     108/598   54/399   0.75 (0.53-1.07)       0.111
   Retroperitoneal   114/807                    24/190            0.90 (0.56-1.44)        0.661                      113/804           25/193    0.92 (0.58-1.45)           0.710             119/815   19/182                                0.71 (0.43-1.18)   0.189     87/598    51/399   0.88 (0.61-1.27)       0.485
   Mediastinum       101/807                    20/190            0.85 (0.51-1.40)        0.516                      100/804           21/193    0.88 (0.53-1.44)           0.603             101/815   20/182                                0.88 (0.53-1.47)   0.633     80/598    41/399   0.77 (0.51-1.14)       0.187
   Others            33/807                     7/190             0.91 (0.40-2.09)        0.822                      30/804            10/193    1.38 (0.66-2.88)           0.388             31/815    9/182                                 1.29 (0.61-2.76)   0.508     23/598    17/399   1.10 (0.58-2.09)       0.763
  Clinical stage                                                                                                                                                                                                                                                                                                     
   I+II+4s           192/807                    41/190            0.91 (0.63-1.32)        0.607                      192/804           41/193    0.89 (0.61-1.29)           0.523             197/815   36/182                                0.81 (0.55-1.19)   0.283     148/598   85/399   0.85 (0.64-1.15)       0.293
   III+IV            179/807                    37/190            0.86 (0.58-1.27)        0.436                      176/804           40/193    0.94 (0.64-1.37)           0.747             183/815   33/182                                0.81 (0.54-1.22)   0.321     143/598   73/399   0.76 (0.56-1.04)       0.088

AOR: adjusted odds ratio; CI: confidence interval. ^a^Adjusted for age and gender, omitting the corresponding stratify factor.
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